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ABSTRACT
Proteins have been termed the building blocks of life due to their involvement in
practically every biological process that occurs in a living organism. For years now, researchers
have sought to uncover the underlying mechanisms employed by biomolecules to carry out such
tasks and functions. Initial understanding of proteins and how they function, at the atomic level,
was revolutionized by the generation of numerous average static structures via X-ray
crystallographic methods. Nevertheless, although one or multiple three-dimensional structures
exist for many proteins, biological activity cannot be solely explained by relatively rigid
structures. Proteins are dynamic entities governed by their dynamic personalities where
biological function is rooted in their internal motions, fluctuations, and conformational changes.
However, despite many experimental and computational efforts, how protein motions or
dynamics couple protein function remains poorly understood. Here, in this work, we employ
standard molecular dynamics (MD) simulations and enhanced sampling methods (Rotatable
accelerated MD-dual boost (RaMD-db)) to try and capture a more accurate representation of the

dynamic nature of two enzymes, cyclophilin A and choline oxidase. We show that molecular
dynamics is a powerful method and is more than capable of acquiring a more accurate
representation of the dynamic nature of the enzymes, in comparison to experimental techniques.
More so, RaMD-db, because it was able to sample conformational states that were never
observed in standard MD. Furthermore, we showed, at an atomic level, how protein motions
facilitate and are coupled to biological function in both cyclophilin A (CypA) and choline
oxidase. Ultimately, an atomic level description of how protein motions facilitate function,
provided by the results in this work, can be utilized for drug design advancement, protein
engineering, and to gain a better understanding of protein participation in disease.

INDEX WORDS: Protein, X-ray Crystallography, Molecular Dynamics, Cyclophilin A,
Communication Pathways, Choline Oxidase, Gated Mechanism, Enhanced Sampling,
RaMD-db.
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1

INTRODUCTION

Proteins are vital for living organisms due to their participation in various biological
processes that are essential for life.1-2 In particular, proteins are responsible for most of the work
performed in cells and are required for the structure, function, and regulation of living tissue,
organs, etc. For example, some proteins like hemoglobin are responsible for the flow and
transport of molecules from one place to another (transports oxygen throughout the body)
(Figure 1A). Other proteins like collagen play a structural role (structural protein found in
connective tissue in animals) and enzymes like amylase catalyze reactions within the body
(breaks down starch into simple sugars) (Figure 1B).

Figure 1. Examples of three-dimensional protein structures
A) Example of a tetrameric transport protein, Hemoglobin (PDB 5NI1 3.2 Å). B) Example of a monomeric
enzyme, Amylase (PDB 1SMD 1.6 Å). C) Illustration of an amino acid primary sequence D) and its threedimensional fold ( Myoglobin, PDB 3RGK 1.65 Å).
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Overall, there are many different kinds of proteins, each with a unique shape, size, and
responsibility, in which its singularity primarily depends on the joining of smaller subunits called
amino acids (Figure 1A, 1B, and 1D). Generally, proteins are made up of one or more long
chains of amino acids where the arrangement of amino acids determines a protein’s threedimensional fold and ultimately its specific function (Figure 1C to 1D). Structural biology
suggests that a folded protein structure is necessary for biological function, but it is not yet
entirely possible to predict a protein’s three-dimensional structure from its primary sequence.1, 3
Experimental techniques like nuclear magnetic resonance (NMR) and X-ray
crystallography are often used to determine the atomic and molecular structures of molecules,
including proteins. X-ray crystallography, specifically, has revolutionized our understanding of
protein structure and its relationship to function through the generation of high-resolution
average static structures (Figure 2).1, 4 The details in these structures, the symmetry, the crevices
that form, and the ability to see molecules in complex, allow one to gain a clearer picture of how
proteins interact with one another and how they are capable of performing a certain activity like
catalysis. Although X-ray crystal structures are detailed enough to provide us with information
regarding function, it is important to remember that biomolecules are not static.1 Proteins are
dynamic entities where internal motions and conformational changes play a role in function.5-6
Biomolecules wiggle, jiggle and sample a large ensemble of conformations.7 In other words,
functional properties of a protein cannot be solely described by the use of relatively rigid
structures. An X-ray crystal structure only displays a static snapshot, thus, analysis of one or
even a handful of X-ray crystal structures may fail to capture the overall nature of a protein. An
X-ray crystallographic structure has been determined for many proteins and provides much
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insight into protein function. However, a more thorough understanding of a proteins
biological function can be gained by watching the protein in action. 4, 8

Figure 2. X-ray Crystallography
Illustration of the steps taken for determining an average three-dimensional crystal structure. A) A beam
of X-rays is aimed at a crystal. B) The x-rays are diffracted onto a detector by the atoms that make up
the crystal. C) Measurement of angles and intensities of the diffracted rays can then be used to produce
an electron density map. D) The result is a three-dimensional atomic model of the molecule.

Molecular dynamics (MD) simulations can be used as the technique to complement the
information gathered from experimentally derived structures. MD is a widely used tool,
implemented for investigating the structure, dynamics, and thermodynamics of biomolecules.9-11
By numerically solving Newton’s equations of motions, MD is capable of generating various
conformations of a protein that differ from those predicted by X-ray crystallographic methods.
An ensemble or trajectory of protein conformations projects the physical movement of atoms of
a particular system as a function of time and allows one to view the internal motions experienced
by biological systems. Any knowledge on motions can provide insight into biological
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phenomena and report information detailing the properties of a system, which are typically not
brought forward by experimental methods.9-10 On another note, the diversity of a protein
ensemble depends on the sampling efficiency of MD.12 Because biological systems have
complex energy landscapes, conformational sampling is not always exhaustive, specifically
when using standard MD.12-13 Protein conformational states are typically separated by energetic
barriers of various heights where it is possible for a system to become trapped in a particular
well, due to high-energy barriers, and not reach other conformational states.12-13 Fortunately,
enhanced sampling methods, accelerated MD and derivatives, have been able to make up for the
sampling limitation of standard MD.12 By adding a bias potential to the potential energy of a
system, barriers that exists between neighboring wells are reduced, allowing a system to sample
conformational states that are not accessible by standard MD.12-13 These methods improve
sampling by increasing the escape rate of a system from potential energy wells, resulting in
better and more diverse representation of conformational phase space.12-13
Because proteins are vital for living organisms and participate in virtually every
biological process that takes place in and out of a cell, the scientific community seeks to decipher
the underlying mechanisms used by biomolecules to carry out their many activities.1-2, 4
Although X-ray crystallography is able to determine three-dimensional structures for various
proteins and it is detailed enough to provide the spatial resolution regarding biological function,
proteins are not static. Proteins are governed by their dynamic “personality” where internal
motions and conformational changes play a part in a proteins overall function.4 In the following
work, we study two enzymes, cyclophilin A (CypA) and choline oxidase. CypA, in particular,
belongs to the family of peptidyl prolyl isomerases (PPIases) and is responsible for catalyzing
the cis-trans isomerization of substrate backbone peptidyl prolyl ω-bonds (Figure 3A). Choline
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Oxidase, on the other hand, belongs to the family of oxidoreductases and is responsible for
catalyzing the chemical reaction of choline to glycine betaine (Figure 3B). Unfortunately,
despite extensive experimental and computational studies, full understanding of how protein
dynamics facilitates or leads to protein function in both these enzymes remains a big challenge.
We used and compared generated conformational ensembles from standard MD and a derivative
of accelerated molecular dynamics (aMD), RaMD-db, in hopes of acquiring a more accurate
representation of the dynamic nature of the enzymes. Furthermore, we also used the generation
of diverse conformational ensembles to better understand how protein motion and
conformational changes facilitate protein function in hopes of gaining more insight for drug
design advancement and engineering of proteins.

Figure 3. Structure of Cyclophilin A and Choline Oxidase
A) Three-dimensional structure of the monomeric enzyme CypA (cyan, PDB 1M9F 1.73 Å), represented in
molecular surface and NewCartoon. B) Three-dimensional structure of the dimeric enzyme choline oxidase
(PDB 4MJW 1.95 Å) , represented in purple and orange molecular surface.
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2

THE CONCEPTS AND METHODS BEHIND MOLECULAR DYNAMICS
Molecular Dynamics methods was first conceived in the 1950’s by Alder and Wainwright

when studying the collisions between hard spheres.14-15 Major advances followed with Rahman,
who used the Lennard-Jones potential to carry out simulations on liquid argon and eventually
performed molecular dynamics simulations on the first realistic system, water.14-15 Since then,
molecular dynamics simulations have evolved allowing the simulation of more biologically
relevant systems. For example, McCammon et al were able to simulate the first protein, a small
bovine pancreatic trypsin inhibitor, for 9.2 ps in the late 1970’s.14
Molecular dynamics (MD) is now used as a promising and mature technique that can be
implemented for better understanding the structure, dynamics, and thermodynamics of
biomolecules9-11. At the present time, computer simulations are used to study and capture the
physical movement of atoms, of a particular system, as a function of time and allow us to view
the internal motions experienced by biological systems. By numerically solving Newton’s
equations of motions, we are able to determine the trajectories of atoms or proteins and
accumulate the many protein conformations that are sampled during a typical molecular
dynamics simulation.
Biomolecules are inherently dynamic, where motions are known to play a functional role,
thus, any knowledge on motions can provide insight into biological phenomena and report
information detailing the properties of a system, which are typically not brought forward by
current experimental methods9-10. The protein conformations sampled during a MD simulation
vary and are distinct from the initial X-ray crystal structures used for the initiation of molecular
dynamics studies. These trajectories or ensembles of protein conformations, collected from MD
simulations, depict a more accurate representation of biological structure and function and can
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serve as useful tools to enhance the knowledge in the areas of structure-based drug design,
protein structure determination, and X-ray structure refinement.
2.1

Potential Energy Function
In order to perform molecular dynamics simulations, given an initial NMR or X-ray

crystallographic structure for a biomolecular system, a suitable energy function (force field) is
needed to describe the intermolecular and intramolecular interactions.14 A force field defines a
system as a set of atoms gripped together by interatomic forces.15 Energy functions are usually
composed of parametrized terms where the parameters are obtained from experimental and
quantum mechanical studies, and are used to describe the bonds, angles, dihedrals, and
nonbonded interactions (electrostatic and van der Waals interactions) in a system.11, 14 There are
many different force fields that have been developed to treat different systems. A typical
expression looks like the following equation (eq.1).

𝑈(𝑟$ , … , 𝑟' ) = ∑12345 𝐾* +𝑟 − 𝑟-. 02 + ∑6378-5 𝐾q +q − q-. 02 +
∑4EF-4*685

9:
;

[1 + cos (𝑛f − g)] + ∑ERS G

HIJ
LM
KIJ

−

NIJ
O
KIJ

+

.I .J
-P KIJ

Q (1)

The potential energy (U) is a function of atomic positions (r) of n atoms, all atoms present in a
system.11 The first term, Equation 2, is a harmonic term based on hook’s law that is used to
control the length between interacting atomic pairs separated by covalent bonds.16

𝑈12345 = ∑12345 𝐾* +𝑟 − 𝑟-. 02 (2)
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Kr is the force constant that determines the strength of the bond, r is the distance between atoms
that are covalently bonded, and req is the equilibrium distance.17 The first term basically describes
energies as the deformation of bond lengths (r) from its equilibrium value (req).15

𝑈6378-5 = ∑6378-5 𝐾q +q − q-. 02 (3)

The second term, Equation 3, describes bond angle bending for a 3 atom center held together by
two covalent bonds. A harmonic potential is also used and the energies are described as the
deformation of bond angles (q) from equilibrium value (qeq).15, 17 Kq is the angle bending force
constant.17

𝑈4EF-4*685 = ∑4Eℎ-4*685

9:
;

[1 + cos (𝑛f − g)] (4)

The third term, Equation 4, is not a harmonic function but a periodic function most often
represented with a cosine function.15-16 The dihedral angle (f) is defined by the twisting of the
bond around the center bond in a four atom center A-B-C-D. Vn is the force constant and the
height of potential/rotational barriers.15-16 n determines the periodicity of the function.15

H

IJ
𝑈3231234-4 = ∑ERS G KLM
−
IJ

NIJ
O
KIJ

+

.I .J
-P KIJ

Q (5)

The last term, Equation 5, describes the non-bonded interactions which can be divided into two
types of interactions: electrostatic interactions and Van der Waals interactions.14 The van der
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Waals repulsive and attractive interatomic forces are modelled by the Lennard-Jones 12-6
potential.15 The R-12 accounts for the increasing repulsion between atoms at short distances due to
the overlapping of electron orbital. The R-6 term accounts for the weak attraction that occurs at
long ranges due to London dispersion. Aij and Bij are parameters which determine the location
and well depth and Rij represents the distance between atoms.14, 16 The interaction between partial
charges is described by the Coulomb potential.15 The atomic partial charges are represented by qi
and qj where the distance between the atoms is represented by (Rij). 14The dielectric
function/constant is represented by er.16
2.2

Molecular Dynamics Methods
By numerically solving Newton’s equations of motions we are able to monitor the time

evolution of a set of interacting particles.11, 15 Newton’s equation of motion is given by Equation
6 where Fi, the force exerted on particle i, is equivalent to the mass of particle i, mi, times the
acceleration,

4M *I (W) 11, 15
.
ri(t) is the position vector of the ith particle at time t.
4W M

𝐹E = 𝑚E

4M *I (W)
4W M

(6)

The force exerted on particle i can also be expressed or calculated by taking the negative gradient
of the potential energy function (eq.1) with respect to the position of the particle as seen in
equation (7).11, 14-15

𝐹E =

Z4[
4*I

(7)
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Upon solving the force acting on each atom, accelerations can be determined. An
algorithm can then be used to predict the position of atoms at a later point, hence generate
movement in a simulation. Several algorithms have been developed to integrate the equations of
motion but the Verlet algorithm, as seen in equation 8, is the simplest most frequently used
algorithm.14-15 It uses the Taylor series approximation to approximate the position of a particle at
time t + ∆t, updated time.14-15 Integrations are typically performed over a serious of steps where
each step is separated by a time step (∆t).14 ∆t is determined by the fast motions in the system
and is typically in the subfemtosecond scale to insure stability of integration.15 As can be seen in
equation 8, the Verlet algorithm defines new positions 𝑟E (t + ∆t) by using the atomic positions
from a previous step 𝑟E (t - ∆t) and the accelerations and atomic positions at time (t).14 The
velocities of the particles can then be calculated by using the new atomic positions 𝑟E (t + ∆t) and
the atomic positions from the previous step 𝑟E (t - ∆t) as shown in Equation 9. The sum of
potential energies and the forces acting on each atom must be calculated at each step in order to
continuously update the positions and velocities of each atom.

𝑟E (𝑡 + ∆𝑡) = 2𝑟E (𝑡) − 𝑟E (𝑡 − ∆𝑡) +

𝑣E (𝑡) =

2.3

*I (W ` ∆W)Z*I (WZ ∆W)
;∆W

4M *I (W)
4W M

∆𝑡 ; (8)

(9)

Limitations
Numerous studies have shown that the measurements made via molecular dynamics

simulations correlate and are in agreement with those calculated via experimental methods.9, 18
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The agreement has validated the use of molecular dynamics. Hence, MD has become a
promising and powerful technique that can be implemented for better understanding the
structure, atomistic movement, and thermodynamic properties of biomolecules.9-10, 18 Aside from
the successes, molecular dynamics still has its limitations which if handled with awareness can
lead to successful use of it.15
Molecular dynamics faces two main challenges, the force field and timescale.18 The force
fields or energy functions are in need of some improvement due to the fact that they are poorly
suited to deal with systems where quantum effects are important.15, 18 Classical atomic force
fields cannot be applied to gain more insight on bond-breaking, bond formation, and the flow of
electrons from one atom to another because atoms are treated using “ball and stick” model.15, 18
For example, the binding of oxygen to hemoglobin in a red blood cell or the cleavage of a
peptide bond by the digestive enzyme chymotrypsin cannot be modelled using atomic forcefields due to changes in bonding.15 Furthermore, atoms are assigned fixed partial charges, which
in reality is not suitable, due to the dynamic nature of the electron clouds surrounding the
atoms.18 Thus, partial charges would be better represented if they were responsive.18 Designing a
force field that can replicate the forces experienced by atoms in vivo and that can be applied to
any system regardless of the surrounding environmental conditions is a difficult project to take
on but can lead to a more accurate representation of life.15
In regards to time, molecular dynamics is limited by short simulation time scales.18
Simulations beyond the microsecond timescale can become computationally expensive because
they require many time steps. As previously discussed, simulations have to take on short time
steps for numerical and integration stability, femtosecond timescale. However, in order to gain
insight to biologically relevant information a molecular dynamics simulation has to be able to
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sample relevant conformational states of a biomolecule.18-19 Unfortunately, biologically
important phenomena like ligand binding or enzyme catalysis typically occurs in the millisecond
time scale or past.18 Following phenomena like the conformational transition from R to T in
hemoglobin would require millions to trillions of sequential steps to possibly capture a
millisecond event, on a femtosecond time step.15 Not to mention, each step has to account for the
size of the system or biomolecule because as previously discussed the sum of potential energies
and the forces acting on each atom must be calculated at each step in order to continuously
update the positions and velocities of each atom. All in all, the size of the system and the
integration of millions and trillions of steps, high computational demands, can be
computationally expensive and pose limitations on the length of a simulation and the size of the
systems used.15, 18 For example, a one microsecond molecular dynamics simulation for a system
of ~25,000 atoms can take months to finish.18
On another note, biological systems tend to have complex and hyper-dimensional energy
landscapes where conformational sampling is not always exhaustive, specifically when using
classical MD simulations.13 As previously discussed, in order to gain insight to biologically
relevant information a molecular dynamics simulation has to be able to sample relevant
conformational states of a biomolecule and reach convergence.18 The time step already makes
convergence a computationally expensive task, in regards to time. But the use of classical MD
simulations takes it a step further. Biological systems can become trapped in potential energy
minima, due to high-energy barriers, for a large number of steps.13 Thus, regardless of the length
of the simulation or the number of steps integrated, we will only be able to sample a portion of a
biomolecules potential energy landscape which is not an accurate representation of its
conformational phase space. However, as of now, it is impossible to tell whether a simulation
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sampled all possible conformations of a biomolecule because we technically don’t know what
their energy landscapes look like. Implementation of refined force fields and algorithms,
modifying and improving the quality, can potentially lead to longer timescale simulations, better
sampling, and enhance the accuracy and stability of MD.
2.4

Advanced Techniques
Molecular dynamics has its drawbacks, but recent advances in computational power,

algorithms, and other techniques has enabled MD to overcome some of the limitations discussed
above. For example, quantum mechanical calculations have been introduced into classical
molecular dynamics forces fields to deal with quantum effects of a system, which are typically
ignored in classical force-fields.18 In this type of hybrid model, quantum mechanics is used to
simulate the areas where chemical processes occur while conventional MD force field is used to
simulate the rest of the system.18 In addition, polarizable force fields have been designed and are
still being developed to account for the changes experienced in charge distribution by a molecule
in response to the surrounding environmental conditions.15-16, 20
Furthermore, in an effort to extensively sample conformational phase space of a
biomolecule, various enhanced sampling techniques, such as accelerated molecular dynamics
(aMD), replica exchange molecular dynamics, and umbrella sampling have been proposed to
accelerate or expedite the sampling of an MD simulation.21-22 One of the studies in this thesis
particularly uses RaMD-db, an improved variant of aMD. These techniques add a bias potential
to the potential energy of a system.12 Whereas aMD applies boost to all the dihedrals and nonbonded interactions of the system, RaMD-db applies bias only to the rotatable dihedrals and to
the potential energy of the non-bonded interactions.12 The bias potential reduces the barrier that
exists between neighboring wells by raising the potential energy wells, allowing the system to
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sample conformational space that is not accessible by conventional MD.12-13 These methods
facilitate sampling by increasing the escape rate of the molecular system from potential energy
wells, resulting in better and faster sampling of the conformational space.13
In addition, the development and use of clusters, supercomputers, and graphical
processing units allow for longer timescales/simulations and the simulation of larger systems.23
In the Hamelberg lab, we have started using graphical processing units which were originally
designed to speed up video games or handle computer graphics.18, 24 Graphics processing units
have accelerated the calculations on our systems by tens of times and have allowed access to the
microsecond timescale using femtosecond time step.18 Recall that biologically relevant
phenomena occurs in the micro to millisecond time scale. On another note, Anton, a
supercomputer built by the De Shaw group, is capable of simulating a system for many
microseconds each day.18, 23 Moreover, the De Shaw group has been able to run simulations
longer than one millisecond and capture biologically relevant phenomena like the folding and
unfolding of a protein and the binding of a drug.18 Conclusively, many alternative methods are
continuously being explored to take on the limitations experienced in MD.
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3

DECODING ALLOSTERIC COMMUNICATION PATHWAYS IN CYCLOPHILIN
A WITH AN EXPLICIT PERTURBATION-RESPONSE ANALYSIS

3.1

Abstract
Protein dynamics has replaced the view of proteins as rigid three-dimensional structures

where internal motions, conformational changes, and/or fluctuations are found to play critical
roles in biological function. However, a consensus on how precisely protein dynamics facilitates
or leads to protein function is yet to be reached. Here, we employ microsecond-long molecular
dynamic simulations to characterize the dynamic nature of Cyclophilin A (CypA), a well-studied
peptidyl-prolyl cis-trans isomerase known to participate in diverse biological processes and has
been associated with many diseases, including cancer. Experimental studies suggest the allosteric
coupling between CypA’s active site dynamics and distal dynamic regions (hotspots) ~15 Å
away from the active site. Nonetheless, atomistic details of the mechanisms underlying the
communication between the distal sites in CypA is lacking. We show, via a combined approach
of single-point mutations on Val29 and Val6 (hotspots), side chain torsion-angle analysis, and
residue-residue contact analysis, that the dynamic distal regions communicate with and induce
change in the active site via three dynamic networks/pathways. Furthermore, a newly developed
method, difference contact network analysis ( dCNA), elucidates the mechanisms underlying
mutation specific allosteric effects. The results complement previous experiments and further
confirms the connection between CypA’s dynamics and its catalytic activity. The atomic level
description of CypA provided by the results in this study can be further utilized for the design of
more potent therapeutics in drug discovery or future protein engineering of CypA.
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3.2

Introduction
Proteins are complex systems that are present in all living organisms and play important

roles in various biological processes essential for life. In early views, proteins adopt a unique
rigid three-dimensional structure determined by the amino acid sequence.25 A paradigm shift has
emerged to incorporate protein dynamics.26-28 Biomolecules sample a large ensemble of
conformations, governed by their free energy landscape, and experience motions spanning a
broad range of time and length scale.7 These conformational fluctuations that occur around an
average native structure are crucial for protein function.5-6 Essentially, internal motions and
conformational changes in enzymes are critical for substrate recognition and release, catalytic
turnover, and allosteric communication or regulation.29 However, despite extensive experimental
and computational studies, how protein dynamics couple protein function remains elusive.30-31
Deciphering the dynamics-function relationship facilitates a better understanding of diseaseassociated mutations and provides means to advance novel drug discovery and protein design.
Cyclophilin A (CypA) is a well-studied enzyme, known to participate in diverse
biological processes including protein folding, regulation of apoptosis, and signaling.32-34 CypA
belongs to the family of peptidyl prolyl cis-trans isomerases (PPIases) and is responsible for
speeding up the slow cis-trans isomerization of substrate backbone peptidyl prolyl ω-bonds
without any bond formation or breakage. Overexpression of CypA is linked to the development
of several types of cancer such as lung cancer, pancreatic cancer, and endometrial carcinoma.35-38
Interactions of CypA with various drugs, like immunosuppressive drug Cyclosporine A and
anticancer drugs, have shown to suppress rejection of organ transplants and reduce the
overexpression of CypA.32-33 Additionally, CypA regulates the infection of various viruses like
human immunodeficiency virus (HIV)-1 and hepatitis C.12, 39-40 The interaction between CypA
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and HIV facilitates viral replication by catalyzing cis-trans isomerization of the -Gly-Pro- motif
found on an HIV-1 capsid loop.32, 41-42 In summary, CypA has become a potential therapeutic
target due to its involvement in various physiological and pathophysiological processes.
Numerous efforts have been devoted to design and development of potent inhibitors for CypA
and the other cyclophilin isoforms.12, 43 Insight into CypA’s dynamics and how they are coupled
to and facilitate substrate recognition and binding, catalysis, and product release can provide the
information needed for developing these inhibitors. The obtained knowledge can be also
leveraged to modulate/engineer CypA to gain the desired new function.
Recent nuclear magnetic resonance (NMR) and computational studies suggest the
allosteric coupling of distal dynamic regions in CypA to active site dynamics.7,29,44 Previous
NMR work by Schlegel et al. communicated the presence of dynamical changes in areas distal to
the active site upon substrate binding, specifically around the residue Val29.44 With molecular
dynamics (MD) simulations and NMR, Doshi et al. discovered a similar distal “dynamic cluster”
~15 Å from the active site.7 Using NMR relaxation techniques and single site multiple mutation,
named RASSMM, Holliday et al. validated the presence of these “hotspot” residues (distal
dynamic regions ~15 Å from the active site, specifically residues Val29 and Val6) in CypA,
which responded to perturbation of the active site via mutations or substrate binding.29 Alongside
the identification of the hotspots (Val6/Val29), their studies also showed an alteration in the
conformational distributions within the active site and a small but significant change in the
catalytic turnover and binding affinity upon single-site multiple mutation of the hotspots,
monitored by NMR ZZ-exchange and other techniques.7, 29 Interestingly, the catalytic
isomerization rates changed in a mutation specific manner. For example, the catalytic
isomerization rate (10.4 s-1 for wild-type) decreased upon V6T (9.1 s-1) and V29L (6.9 s-1)
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mutations but increased in V29T (12.3 s-1). A similar varying pattern was seen in the binding
affinity, where the dissociation constant substantially decreased from 76 µM for wild-type to 48
µM for V6T and to 38 µM for V29L but only slightly decreased to 73 µM for V29T. These
experiments suggest a negative correlation between catalytic isomerization and binding affinity.
Holliday et al. further identified key residues that when mapped to structure bring forward two
potential allosteric networks, termed “response 1” and “response 2”, by which the localized
motions surrounding Val29 communicates with the active site.29 Notably, our recent simulation
studies show that the two networks are likely conserved across cyclophilin isoforms.45 The same
experimental analysis was performed on Val6 but no allosteric network was identified due to
weak signals.
In this work, we explore the conformational dynamics of wild-type CypA and the four
CypA variants tested in the NMR experiments (V6I, V6T, V29L, and V29T).29 It has been
suggested that biological mechanisms can be deciphered by studying the dynamics of individual
residues and their contributions to global conformational dynamics and stability.46 Using
multiple-microsecond-long atomistic conventional MD simulations, we examine how single-site
mutations, made 15 Å away from the active site, affect conformational changes in the active site
and how these changes might influence enzyme’s function. In particular, we employed a
combined approach of side chain torsion-angle analysis and the residue-residue contact analysis
previously described7, 47, which helps to gain atomistic details of the mechanisms underlying the
communication between distal sites in CypA. We identify three potential communication
pathways: two resemble the allosteric networks identified by Holliday et al., which mainly
mediate the communication between Val29 and the active site, and the third is a novel pathway
possibly responsible for the communication between Val6 and the active site. We further
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elucidate mechanisms underlying mutation specific allosteric effect using a network analysis
method of residue-residue contacts. Our results suggest that a detailed atomistic level
characterization on residue motions in CypA can provide insights into enzymatic function and
regulation, which can be further utilized for drug discovery and protein engineering targeting
CypA in the future.
3.3

Methods

3.3.1 Molecular dynamics simulations
Multi-microsecond MD simulations for five CypA systems (wild-type, V6I, V6T,
V29L, and V29T; each 2.1 µs) were conducted by using the Amber 1448 molecular simulations
program package, along with the force-field 14SB49 and the re-optimized parameters for the w
torsional angle.50 All simulations were performed under substrate-free conditions. The
crystallographic structure of CypA (PDB: 1M9F) was used as the starting conformation of
simulations. Mutations were introduced by first removing all side chain atoms of Val29 and
changing the valine to the corresponding name in the mutant. Missing side chain atoms were
then added by Xleap of Amber14.48 Each system was solvated in an octahedron box filled with
pre-equilibrated explicit TIP3P water molecules.51 The systems were neutralized with chloride
ions. Initial minimization was performed for 1000 steps of steepest decent followed by 4000
steps of conjugate gradient, under position restraints for all protein atoms with the harmonic
restraint force constant k=300 kcal/mol/Å². Each system was then heated up from 100 K to 300
K in two steps of restrained NVT simulations: a short 0.5 ns restrained MD simulation with
restraint force constant k=200 kcal/mol/Å² followed by a 1 ns restrained MD simulation (k=100
kcal/mol/Å²). Equilibration was conducted for 1 ns without any harmonic restraint. Subsequent
production MD was then performed under the same conditions as equilibration. Constant
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temperature (300 K; Langevin thermostat with a collision frequency of 1.0 ps-1) and pressure (1
bar; Monte Carlo barostat with a coupling constant 1.0 ps) along with periodic boundary
conditions were applied. Long-range electrostatic interactions were evaluated via the particle
mesh Ewald summation method52 and short-range nonbonded interactions were treated with a
cutoff of 9.0 Å. The SHAKE algorithm53 was used to constrain bonds involving hydrogens. A
time step of 2 fs was used for all simulations to integrate the equation of motion.
3.3.2 Side chain torsion-angle analysis
CPPTRAJ of the AmberTools suite of programs54, along with in-house written
programs, were used to calculate the side chain c torsion angles. All molecular graphics were
generated using VMD.55
3.3.3 Contact analysis
From the simulations, a set of residue-residue contacts was created of size N(N-1)/2,
where N=165 is the number of residues in CypA.7, 47 When two heavy atoms were within a range
of 4.5 Å of one another, their respective residues were considered to have formed a contact. The
4.5 Å cutoff was chosen by taking into consideration various forces, including van der Waals
interactions and hydrogen bonding, that are present at this interval and suggests potential
residue-residue contacts.7, 47, 56 However, the contacts of interest were those that perpetually form
and break in the trajectories; contacts that persist for a minimum of 10% and a maximum of 90%
are defined as “meaningful” dynamic contacts.7, 47
Difference contact network analysis ( dCNA), was performed by first building a
consensus network across input systems. In the consensus network, an unweighted edge
between residues was added if the corresponding contact probability is stable (f≥0.9) across all
the systems. Residue communities were then detected using the Girvan-Newman’s algorithm57,
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where the number of communities was determined by maximizing modularity. Difference intercommunity contact probability between two systems was computed by summing up the
probability changes of all contacts connecting the two communities. Network analysis and
associated graphics generation were performed with Bio3D.58-59
3.4

Results and Discussion

3.4.1 Alteration of CypA active site dynamics upon distal mutations

Figure 4. Dynamical changes in CypA's active site upon point mutations
(A) Three-dimensional structure of CypA (white) depicting two mutation sites, Val6 and Val29 (red
spheres), and two active site residues, Arg55 and His126 (yellow licorice). (B) Probability density
distribution of the distance between the Cz of Arg55 and the Ca of His126 for wild-type (black) and
mutants including V6I (red), V6T (green), V29L (blue), and V29T (brown).

Distal mutations cause conformational changes in the active site of CypA. Multiple
microsecond (totaling 10.5 µs) molecular dynamics simulations of CypA wild-type and mutants,
including V6I, V6T, V29L, and V29T, were carried out. The mutation sites were chosen based
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on previous experimental studies, where using NMR ZZ-exchange Holliday et al. found that a
single point mutation at Val6 or Val29 induced small but significant changes in active-site
binding affinity and catalytic turnover in CypA.7, 29 Active site dynamics were characterized by
the distance between the guanidinium carbon (Cz) of Arg55 and the alpha carbon (Ca) of
His126. The side chain motions of Arg55 were monitored due to its involvement in the
stabilization of the transition state of substrates.7 It shows that although both Val6 and Val29 are
distal from the active site (Figure 4A), mutations at these sites cause a notable shift of
probability density distribution of the Arg55-His126 distance specific to the substituting amino
acid (Figure 4B). The distance displays a multimodal distribution peaking at similar positions
across systems. In the wild-type (Figure 4B, black), the major peak of distribution appears at
~16 Å. In all the mutants, the population at ~16 Å drops substantially whereas the population at
other positions increases. In particular, V29L (Figure 4B, blue) has a dramatic increase of
population at ~13 Å while V6T (Figure 4B, green) possesses an enhanced population at a longer
distance (~19 Å). The variable active site dynamics (Figure 4B) correlate with the
experimentally observed varying binding affinity and/or catalytic isomerization rate among
CypA wild-type and variants. Specifically, the results suggest that an increase of population at
short Arg55-His126 distance (as seen in V29L) may lead to an enhanced binding affinity and
reduced catalytic turnover rate. Furthermore, the multimodal distribution indicates an intrinsic
movement of the side chain Arg55 toward and away from the active site within each system,
which potentially creates a tighter or looser pocket for substrate binding. Our results suggest that
the mutations might affect substrate binding affinity and/or catalytic turnover by altering the
shape and dynamics of the binding pocket.
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3.4.2

Identification of communication pathways coupling distal residues to the active site

Figure 5. Probability density distribution of the side chain torsional angles for select
residues in and out of the CypA binding pocket.
Depicted are the c torsion angles derived from the five simulations performed: wild-type (black), V6I (red),
V6T (green), V29L (blue), and V29T (brown). Each panel shows the angles for a specific residue.

Changes of side chain dynamics in response to the mutations are distinct among CypA
residues. Side chain dynamics were characterized by probability density distributions of c
torsion angles for all 165 residues (except for alanines and glycines) derived from MD
simulations of wild-type CypA and its variants. It shows that, like the Arg55-His126 distance,
most c-angles display a multimodal distribution with peaks of distribution for the same angle
located at similar positions across systems (Figure 5; see also Appendix A.1 for the full result).
This indicates that upon the mutations energetically stable/metastable conformations of side
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chains are largely retained, although in some residues relative population between conformations
may shift in a mutation-dependent manner. To quantitatively measure changes occurring in a
residue, we computed the maximal variance of probability distributions over all angles belonging
to the residue. Top 40 residues having the largest c-distribution changes upon the mutations are
defined as “key” residues, which are located both in and out of the substrate binding pocket
(Figure 5 and Appendix A.1). For example, Lys31, Ile89, Asn102, Phe113, and Trp121 all
display significant changes in at least one c angle and are identified as the key residues (Figure
5A-E). Among them, Asn102 and Phe113 are active site residues known to form key hydrogen
bonds with the substrate or form the substrate binding surface.60-61 Trp121 does not participate in
the formation of CypA’s binding pocket but it is found to interact with the substrate via hydrogen
bonding.61 Even slight changes in the rotameric state of these residues might directly affect the
substrate binding affinity and/or catalytic activity. In contrast, Lys31 and Ile89 are located far
(~16-17 Å) away from the active site and do not participate in substrate binding or catalysis
directly. Thereby, these residues are representatives of a group of residues mediating the
coupling between the mutation and active sites. As a control, the c-distributions of a non-key
residue distal from the active site, Glu134, are almost identical between wild-type and mutants
(Figure 5F). This residue represents the 119 CypA residues whose side chain dynamics are
largely unaltered upon the mutations (See Appendix A.1).

25

Figure 6. Comparison of dynamical communication pathways identified in CypA via
experimental and computational mutagenesis
(A, B) The Response 1 and Response 2 allosteric networks identified via experimental NMR relaxation
techniques for the Val29 mutations.29 Residues constituting the networks are represented as molecular
surface. The arrows highlight the direction of communication from mutation site to the active site. (C, D)
Communication pathways from the Val6/Val29 mutation site to the active site identified via the side chain
torsion-angle analysis of MD simulations for CypA wild-type and mutants. Residues participating in the
pathways are represented as molecular surface and are grouped into three clusters corresponding to three
distinct pathways: Pathway 1 (blue), Pathway 2 (red), and Pathway 3 (yellow).
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The key residues identified from residue torsion-angle analysis delineate pathways for
allosteric communications largely consistent with recent NMR experiments. Using a combined
site-directed mutagenesis and NMR relaxation techniques, Holliday et al. recently identified
two distinct allosteric networks, termed “response 1” and “response 2”, which potentially
mediate the coupling between the active site and the distal Val29 mutation site (Figure
6A,B).29 Similar measurements were done on the Val6 mutation site but no clear signal was
detected. With MD simulations, we directly measured residue responses to the same mutations
as in experiments introduced at Val29 and Val6. The top 40 residues exhibiting the largest
changes in the c torsional probability distributions between wild-type and mutants occupy
regions in the CypA structure largely overlapped with the experimentally derived allosteric
networks (Figure 6C,D; to show complete pathways we incorporated the 6 active site residues,
i.e. Arg55, Phe60, Met61, Gln63, Ala101, and Gln111, in the figure, which are not all in the
top-40 list but did experience significant changes in c-distributions except for Ala101; See
Appendix A.1). In addition, MD simulations were able to identify more residues, leading to
better defined pathways than NMR (Figure 6). Both MD and NMR defined pathways connect
Val29 and the active site, indicating that these pathways are mainly responsible for mediating
the allosteric effect caused by mutations at Val29.
MD simulations and the side chain torsion-angle analysis identify a novel pathway that
potentially mediates communications between Val6 and the active site (Figure 6D, yellow).
The new pathway goes from the peripheral b-sheet, where the Val6 is located, to the bottom of
the substrate binding pocket and is shorter than the other two pathways. This pathway was not
observed in NMR experiments due to the weak signals upon Val6 mutation. This indicates that
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MD and associated analysis methods are more sensitive and are able to provide new insights
into the allosteric mechanisms of CypA mediated catalysis complementary to experiments.

Figure 7. Dynamical communication pathways identified in CypA via residue-residue
contact analyses
(A) and (B) depict different orientations of the pathways. Residues involved in the pathways are
represented as molecular surface and are clustered into three groups by comparing with the pathways from
the torsion-angle analysis: Pathway 1 (purple), Pathway 2 (green), and Pathway 3 (orange). Arrows indicate
the direction from the Val6/Val29 mutation site to the active site. The pathways were identified via contact
analyses on the MD simulations of CypA wild-type and mutants.

3.4.3 Residue-residue contact analysis supports the proposed communication networks in
CypA
Residue-residue contact analysis reveals communication networks in CypA similar to
those derived from NMR and the torsion-angle analysis. Here, we used a similar contact analysis
method as previously described.7, 47 A contact is defined by two nonadjacent residues whose
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minimal non-hydrogen atomic distance is within 4.5 Å. The formation probability of a specific
contact during the simulation trajectory is then calculated. Contacts with averaged formation
probability across systems being 10-90% are defined as “dynamic contacts”, which are
considered to be important for allosteric communications. Top 40 residues involved in dynamic
contacts exhibiting the largest probability changes among systems, measured by variance of
probabilities, were identified (See Appendix A.2 for the statistics of all dynamic contacts) and
mapped to the CypA structure. It shows that the 40 residues delineate pathways resembling those
derived from NMR and the side chain torsion-angle analysis of MD simulations (Figure 7,
purple and green; to show complete pathways we incorporated the 7 active site residues, i.e.
Arg55, Phe60, Met61, Gln63, Phe113, Gln111, and Leu122 in the figure). These pathways likely
mediate the Val29 mutations induced allosteric effect. The consistency is not surprising because
by definition contact dynamics should be correlated with side chain motions, the latter being
predominantly represented by c-angle dynamics. Intriguingly, contact analysis identifies 3
residues on the peripheral b-sheet but these residues do not form a complete pathway to the
binding pocket (Figure 7, orange). Considering the same 40-residue threshold used for both
methods, this result indicates that torsion-angles are more sensitive than contacts and can capture
subtle signals that might be related to the allosteric effect caused by mutations at Val6.
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3.4.4 Contact analysis provides insights into mechanisms underlying mutation specific
allosteric effects.

Figure 8. Difference contact network analysis reveals mutation specific dynamical
changes between segments of residues in CypA
(A) Residues are grouped based on a community analysis of the consensus contact network across wildtype, V29T, and V29L (See text for detail). Residues in the same group are mapped in the CypA structure
using the same color. (B,C) Community networks represented by colored circles (as in A) and lines. The
radius of circles is proportional to the number of residues in the corresponding community. Lines linking
circles describe overall contact probability changes (df) between the communities from wild-type to (B)
V29T or (C) V29L. Blue and red lines indicate significantly (|df|≥0.1) enhanced and reduced, respectively,
contact probabilities upon mutations. Lines with |df|<0.1 are colored gray. The width of lines is determined
by |df| (and the corresponding df value is shown for lines with |df|≥0.1).

Difference contact network analysis reveals a residue community structure that is
common across CypA wild-type and mutants. To better understand conformational changes
conveyed in residue-residue contacts, we employed a recently developed method for
comparative protein structure network analysis (See Methods for detail). Similar ideas have
been implemented in the dynamical network analysis originally proposed by Luthey-Schulten
and colleagues62 and widely applied to different biological systems.63-67 However, our new
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method is different from previous methods in two aspects: 1) Instead of building a network for
each system independently and comparing networks afterwards, the new method incorporates
two or more systems as input and builds a consensus network over them. This solves a problem
in previous network comparisons that the definition of residue communities varies among
systems impeding the comparison of inter-community connections. 2) Dynamical information
in previous methods is characterized by residue-residue cross-correlations, while in the new
method it is represented by dynamical changes of contacts between systems. Thereby, the new
method can capture larger-amplitude conformational changes. Three CypA systems were
compared: wild-type, V29T, and V29L. The two mutants represent two extreme cases of
allosteric regulation in CypA-V29T causes the strongest positive allosteric modulation of
catalysis (highest turnover rate) while V29L causes the strongest negative allosteric modulation
(lowest turnover rate) in the survey of point mutations at Val6 and Val29.29 The derived
consensus network reveals 7 residue communities or subdomains (Figure 8). Intriguingly, the
binding pocket is approximately equally partitioned into two communities (Figure 8A, gray
and tan). A similar bilobal partition is observed in the peripheral b-sheet under the binding
pocket (Figure 8A, red and blue). At last, three loops are identified as independent
communities (Figure 8A, orange, silver, and yellow), which account for the major flexibility of
CypA.
Dynamical changes between communities elucidate mechanisms underlying mutation
specific allosteric effects. V29L displays overall more remarkable dynamical changes with
respect to wild-type than V29T (Figure 8B and C). Major inter-community changes in V29L
are shown to be associated with the three loop-dominant communities (Figure 8C, orange,
silver, and yellow circles). Changes in the same regions are relatively mild in V29T (Figure
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8B). This is consistent with the experimentally determined allosteric effects of these mutations,
where V29L shows the largest deviation from wild-type in both substrate binding affinity (50%
increase) and cis-trans turnover rate (34% decrease) among all the tested mutations whereas the
corresponding difference in V29T are much smaller (4% increase for binding and 18% increase
for catalysis).29 Intriguingly, despite the overall same trend of contact formation and breakage
upon both mutations, two sets of inter-community contacts display opposite changes between
the two mutations: contacts between two loop communities (Figure 8B and C, silver and
yellow circles) are more often formed upon V29T while they are more often broken upon V29L
and contacts between the binding-pocket communities are more often broken upon V29T while
they are more often formed upon V29L (Figure 8B and C, gray and tan circles). Strengthened
loop-loop contacts and weakened binding-pocket contacts are also characteristics of the
transition from the substrate-free to substrate-bound state in CypA and other cyclophilin
isoforms45, which may be key determinants of the distinct allosteric effects elicited by V29L
and V29T mutations.
3.5

Conclusions
In this study, multiple microsecond molecular dynamics simulations of CypA wild-type

and mutants, including V6I, V6T, V29L, and V29T, were carried out to provide an atomistic
level description of the mechanism underlying the coupling between the active site of CypA and
a distal dynamic region. Our results suggest that the varying catalytic activity displayed by CypA
upon mutations of Val6 and Val29, as previously described,29 is possibly due to a shift in the
conformational/rotameric populations sampled by the active site residues in comparison to wildtype. In particular, the side chain motion of Arg55, a residue that is important for binding and
catalysis, varied across mutations as shown in the Arg55-His126 distance probability
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distributions (Figure 4B). Changes in active site dynamics can affect the binding affinity or
isomerization directly by modifying interactions determining the shape and dynamics of the
binding pocket. Analyses of side chain torsion-angle distributions from simulations identified
dynamically “sensitive” residues to mutations located both in and out of the binding pocket
(Figure 5). These residues delineate three pathways connecting the hotspot residues (Val6 and
Val29) to the active site and explaining how binding affinity and catalysis are modulated by
mutations at the hotspots (Figure 6). Two pathways are similar to those identified by NMR29 and
both previous45 and current residue-residue contact analyses (Figure 7), which likely mediate the
allosteric communication between Val29 and the active site, whereas the third is a new pathway
possibly mediating the communication between Val6 and the active site. The novel discovery
indicates that the torsion-angle analysis is a sensitive and powerful tool to capture subtle
dynamical changes due to perturbation. Furthermore, a newly developed difference contact
network analysis method was applied to describe mutation specific dynamical changes (Figure
8) and revealed that the characteristic residue-residue contact changes involving three flexible
loops of CypA may underlie the strong substrate binding affinity and slow catalytic turnover rate
of the V29L mutant. Overall, the identification and mapping of the dynamical changes observed
in CypA upon mutations at the atomistic level are of crucial importance for understanding the
relationship between function and dynamics in CypA. Our findings can be further utilized to
advance drug discovery and protein engineering specifically targeting CypA.
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4

ROLE OF F357 AS AN OXYGEN GATE IN THE OXIDATIVE HALF-REACTION
OF CHOLINE OXIDASE

4.1

Abstract
Choline oxidase from Arthrobacter globiformis catalyzes the oxidation of choline to

glycine betaine by using oxygen as an electron acceptor. A partially rate limiting isomerization
of the reduced wild-type enzyme during the reaction with oxygen was previously detected using
solvent viscosity effects. In this study, we hypothesized that the side chains of M62 and F357,
located at the entrance to the active site of choline oxidase, may be related to the slow
isomerization detected. We engineered a double-variant enzyme M62A/F357A. The kinetic
characterization of the double-variant enzyme showed a lack of the isomerization detected in
wild-type choline oxidase, and a lack of saturation with an oxygen concentration as high as 1
mM, while most other kinetic parameters were similar to those of wild-type choline oxidase. The
kinetic characterization of the single-variant enzymes established that only the side chain of
F357 plays a role in the isomerization of choline oxidase in the oxidative half-reaction.
Molecular dynamics studies suggest that the slow isomerization related to F357 is possibly due
to the participation of the phenyl ring in a newly proposed gating mechanism for a narrow
tunnel, assumed to regulate the access of oxygen to the reduced cofactor.
4.2

Introduction
Choline oxidase (EC 1.1.3.17, choline:oxygen 1-reductase) catalyzes the oxidation of

choline to glycine betaine through two subsequent hydride transfer reactions to the flavin
cofactor. The hydride transfers represent the rate-limiting steps in the overall turnover of this
enzyme.68 After each hydride transfer, the reduced flavin cofactor is oxidized by oxygen.68

34

Recent reviews69-70 have summarized the important contributions of many mechanistic,
structural, and computational studies of the oxygen reactivity of flavin hydroquinones. Important
features for the reaction with oxygen, other than accessibility to the reaction site, include a
positive charge and a nonpolar environment near the flavin cofactor, which in choline oxidase
are provided by the positively charged reaction product of the oxidation of choline and V464,
respectively.71 A single electron transfer to oxygen initiates the reaction of the reduced flavin
with oxygen, yielding the radical pair O2• - and flavosemiquinone.72-73 This step is required
because the diradical nature of the most stable form of O2 in the atmosphere has two unpaired
electrons with parallel spins in the π*2p orbitals, thereby precluding direct transfer of an electron
pair with opposite spins from a flavin hydroquinone.69, 73-74 A mechanistic investigation of the
oxygen reactivity of choline oxidase concluded that the oxidation of the anionic hydroquinone to
oxidized flavin and hydrogen peroxide occurs without stabilization of any detectable
intermediate. 75 A synchronous transfer of a hydrogen atom from the N5 atom of the cofactor and
of a proton from a solvent exchangeable site to oxygen was also established in that study.75
Moreover, an inverse hyperbolic behavior of the normalized kcat/Kox value of choline oxidase
with increasing solvent viscosity established the presence of a partially rate limiting
isomerization of the reduced enzyme in the reaction with oxygen during turnover of choline
oxidase,75 which was not observed in other oxidases. Indeed, solvent viscosity studies performed
on bovine serum copper-dependent amine oxidase detected no effect of viscosity on the kcat/Kox
value, indicative of oxygen diffusion not being rate-limiting for the oxidation of the reduced
enzyme.76 Alternatively, a mechanistic investigation of flavin-dependent glucose oxidase showed
a linear positive effect of increasing solvent viscosity on the normalized kcat/Kox value, which is
consistent with the access of oxygen to the active site being partially controlled by the diffusion

35

of the gas into the active site of the enzyme.77 The isomerization detected in choline oxidase in
the oxidation of the reduced enzyme was not further investigated, but it could represent a
conformational change in the enzyme that possibly gates access of oxygen to the reaction site
with the reduced flavin.
Specific hydrophobic cavities that allow the diffusion of a gas from the surface to the
reaction site in enzymes have been previously identified, as in the case of crystals of copper
amine oxidase saturated with xenon.78 Transport pathways for oxygen have been investigated
with molecular dynamics and site-directed mutagenesis studies in copper amine oxidase,78-79
cytochrome c oxidase,80 12/15-lipoxygenase,81 D-amino acid oxidase,82 cholesterol oxidase type
I and II,83-84 and aryl-alcohol oxidase.85 In the case of choline oxidase, a tunnel to the active site
for choline access and glycine betaine release, gated by the side chains of a hydrophobic cluster
composed of M62, L65, V355, F357, and M359, has been identified by molecular dynamics
studies (Figure 9).86

Figure 9. Entrance to the active site of choline oxidase
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(A) Open conformation of loop 250−255 as observed in choline oxidase in complex with the product
glycine betaine (Protein Data Bank entry 4MJW). (B) Closed conformation observed in choline oxidase in
complex with DMSO (Protein Data Bank entry 2JBV). The side chains of M62, L65, V355, F357, and
M359 of subunit B are shown as green spheres. The surface of subunit A at the dimer interface is shown as
a magenta surface. The side chain of F253 of subunit A is highlighted by magenta sticks. FAD is shown in
a variant of CPK coloring with yellow carbons.

A recent study of the crystal structure of choline oxidase in complex with the glycine betaine
product of choline oxidation highlighted the importance of the location of the entrance to the
active site at the dimer interface and the interaction of the hydrophobic cluster with the other
subunit of dimeric choline oxidase.87 Indeed, two different conformations of loop 250-255 at the
dimer interface are related to open and closed conformations of the active site entrance in the
dimeric enzyme. In the open conformation, the side chain of M62 is pointing away from F357
and contacting instead F253 from the other subunit, allowing direct access from the surface of
the enzyme to the flavin in the active site (Figure 9A).87 In the closed conformation, however,
the side chains of M62 and F357 face each other and are in close contact, thereby precluding
access from the surface to the active site of the enzyme (Figure 9B).87 Size exclusion
chromatography and nondenaturing polyacrylamide gel electrophoresis established a
concentration-independent dimeric state for choline oxidase in solution,88 consistent with the
notion that the open and closed conformations related to the hydrophobic cluster at the dimer
interface observed in the crystal structure of the enzyme may have mechanistic relevance.
Here, we have hypothesized that the isomerization of the reduced enzyme may give rise
to solvent viscosity effects during turnover of choline oxidase with choline and may be
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associated with the change in the conformation of the side chains of M62 and F357 observed in
structural studies. The double variant M62A/F357A and the single variants M62A and F357A of
choline oxidase were prepared and characterized by using steady-state kinetics, solvent viscosity
effects, and molecular dynamics. The relative contributions of the M62 and F357 side chains
were dissected. This study provides insight into the partially rate limiting isomerization in the
reaction of the reduced Flavin with oxygen in a flavoprotein oxidase.
4.3

Methods

4.3.1 Enzyme Assays
The effect of relative solvent viscosity on the app(kcat/Kox) value of the three variant
enzymes was investigated at 25 °C in 50 mM sodium pyrophosphate (pH 10.0) using glycerol as
viscosigen, using the same procedure and conditions previously used for wild-type choline
oxidase.75 The viscosity values at 25 °C of the reaction mixture at the varying concentrations of
glycerol were calculated using relative viscosities at 20 °C, available from Lide.89
4.3.2 Data Analysis
The kinetic parameters at a fixed concentration of organic substrate and varying oxygen
concentrations were obtained from the Michaelis-Menten equation using KaleidaGraph (Synergy
Software, Reading, PA). Steady-state kinetic data at varying choline and oxygen concentrations
were fit to eq 1 in the case of enzymes M62A/F357A and M62A and to eq 2 for enzyme F357A
using Enzfitter software (Biosoft, Cambridge, U.K.). Equation 1 is for a sequential steady-state
kinetic mechanism, where v0 represents the initial velocity, e is the concentration of the enzyme,
kcat is the first-order macroscopic rate constant for enzyme turnover at saturating concentrations
of both choline and oxygen, Kch and Kox are the Michaelis constants for choline and oxygen,
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respectively, and Kia is a kinetic constant that accounts for the intersecting line pattern in the
double-reciprocal plot. Equation 2 represents a sequential steady-state kinetic mechanism of the
type described by eq 1 when Kch ≪ Kia Kox.90
𝑉c
𝑘f6W [𝐶𝐻][𝑂; ]
=
𝑒
𝑘fF [𝑂; ] + 𝑘2j [𝐶𝐻] + [𝐶𝐻][𝑂; ] + 𝑘E6 𝑘2j

(1)

𝑉c
𝑘f6W [𝐶𝐻][𝑂; ]
=
𝑒
𝑘2j [𝐶𝐻] + [𝐶𝐻][𝑂; ] + 𝑘E6 𝑘2j

(2)

Solvent viscosity effects on the kcat/Kox values were calculated by dividing the value of
this kinetic parameter determined in the absence of the viscosigen by the value determined in the
presence of glycerol.
4.3.3 Molecular Dynamics (MD)
Three 110 ns molecular dynamics simulations were conducted using the Amber 1091
molecular simulations program: a 110 ns MD simulation on the substrate-free wild-type choline
oxidase and two 110 ns MD simulations of the F357A and M62A enzyme variants. Protein Data
Bank (PDB) entry 4MJW, with resolution of 1.95 Å, of choline oxidase from Arthrobacter
globiformis was used for all simulations. All of the simulations were performed on substrate-free
choline oxidase in the explicit TIP3P water model,92 in a periodic octahedron box, and with the
ff14SB force field parameters93 at a temperature of 298 K. The systems were neutralized with
sodium ions. All simulations were also conducted using the NTP ensemble at a constant pressure
of 1 bar. Initial minimization was performed on the systems for 1000 steps with harmonic
constraints of 100 kcal mol-1 Å-2, followed by a short 0.5 ps MD simulation with harmonic
constraints of 50 kcal mol-1 Å-2, and a 1 ns MD simulation with harmonic constraints of 25 kcal
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mol-1 Å-2. Final equilibration was conducted for 1 ns without any harmonic constraints. The
SHAKE algorithm53 was used to restrain all bonds involving hydrogen, and the Langevin
thermostat, with a collision frequency of 1 ps-1, was used to maintain the theoretical temperature
at 298 K. The long-range electrostatic interactions were evaluated via the particle mesh Ewald
method,94 and a cutoff of 9.0 Å was used for the nonbonded interactions. A time step of 2 fs was
used for all three MD simulations to integrate Newton’s equation of motion. PTRAJ, an analysis
program within the AmberTools suite of programs,54 and Xmgrace, a plotting program, were
used to represent the χ dihedral angle distribution of the hydrophobic cluster amino acids
produced by the MD simulations. To obtain information about tunnel and channel formation
within the enzyme, PTRAJ was used to convert the existing trajectory frames into PDB format,
and CAVER 3.0, software for tunnel analysis and visualization, was used to calculate tunneling.
4.4

Results

4.4.1 Solvent Viscosity Effects on kcat/Kox
The effect of increasing solvent viscosity on the kcat/Kox value of the enzyme variants was
investigated to evaluate whether the mutations impacted the isomerization of the reduced enzyme
that occurs in wild-type choline oxidase during turnover with choline.75 Indeed, a previous study
demonstrated an inverse, hyperbolic solvent viscosity effect on the normalized kcat/Kox value of
the wild-type enzyme.75 The effect of glycerol as a viscosigen on the kcat/Kox value of the
M62A/F357A enzyme variant was investigated here, under the same conditions previously used
for wild-type choline oxidase.75 The solvent viscosity effect with the M62A/F357A enzyme was
negligible as illustrated in Figure 10.
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The effect of increasing glycerol on the kcat/Kox value of the singly mutated enzymes was
also investigated. The F357A enzyme variant displayed a behavior similar to that of the M62A/
F357A enzyme, with the kcat/Kox value being independent of solvent viscosity (Figure 10). In
contrast, the M62A enzyme variant showed an inverse, hyperbolic viscosity effect comparable to
the one previously reported for wild-type choline oxidase (Figure 10).75

Figure 10. Solvent viscosity effect on the kcat/Kox values of wild-type choline oxidase and
mutated enzymes
Solvent viscosity effect on the kcat/Kox values of mutated enzymes at pH 10.0 and 25 °C, with glycerol as a
viscosigen. The normalized kcat/Kox values are shown as a function of relative viscosity for the
M62A/F357A (A), F357A (B), M62A (C), and wild-type (D) enzymes. The dashed line with the slope of 1
represents the theoretical behavior of a fully diffusion-limited reaction, and the dashed line with the slope
of 0 represents the result expected for a lack of diffusion control. Error bars are shown.
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4.4.2 Kinetics with M62A/F357A, M62A, and F357A Enzymes
The steady-state kinetics of the variant enzymes was investigated by monitoring oxygen
consumption at varying concentrations of choline and oxygen at pH 10.0 and 25 °C. The high pH
value was chosen because it represents the independent region for the kinetic parameters in
choline oxidase and all enzyme variants investigated thus far, including H99N, S101A, E312Q,
H351A, H466A, V464A, and N510A.68, 95 The best fit of the steady-state kinetic data with the
M62A/F357A and M62A enzyme variants was obtained with eq 1, establishing a sequential
steady-state kinetic mechanism as in the case of wild-type choline oxidase.68 The best fit for the
F357A enzyme variant, instead, was obtained with eq 2, which represents a particular case of
sequential steady-state kinetic mechanism in which the Kch value is negligible,90 as shown by the
lines intersecting at the origin in the Lineweaver-Burk plot of Figure 11. Interestingly, both the
M62A/F357A and F357A enzyme variants could not be saturated with oxygen concentrations as
high as 1 mM. Also, the M62A/F357A and F357A enzyme variants showed a 5-fold decrease in
the kcat/Kox value, when compared to that of wild-type choline oxidase.68 In contrast, the kcat/Kox
value of the M62A enzyme variant was <2-fold lower than in the wild-type enzyme (Table 1).
Table 1. Kinetic Parameters of Choline Oxidase Variants Substituted at M62 and F357a

M62A/F357A

M62A/F357A

M62A

Wild type

Kcat(S-1)

ndb

ndb

19±1

60±1

Kch(mM)

1.0 ± 0.4

−

0.13 ± 0.02

0.25 ± 0.01

Kox (mM)

ndb

ndb

0.21 ± 0.02

0.69 ± 0.03

kcat/Kch (M-1 s-1)

65000 ± 23000

ndb

150000 ± 23000

237000 ± 9000

kcat/Kox (M-1 s-1)

19000 ± 1000

17000 ± 1000

89000 ± 10000

87000 ± 4000

c
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Kinetic parameters of choline oxidase variants substituted at M62 and F357a. aInitial rates determined as oxygen
consumption at varying concentrations of choline and oxygen in 50 mM sodium pyrophosphate (pH 10.00) and 25
°C. bSaturation could not be achieved because of the limited solubility of oxygen. cData were fit to eq 2, for which
Km value for choline is negligible and could not be determined.

Figure 11. Steady-state kinetics of the M62A/F357A, M62A, and F357A choline oxidase
mutated enzymes
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Steady-state kinetics of the M62A/F357A, M62A, and F357A enzymes performed at 25 °C in 50 mM
sodium pyrophosphate (pH 10.0). (A) Dependence of the initial rate on oxygen concentration for the
M62A/F357A enzyme at choline concentrations of 20 (●), 7 (■), 2 (○), 1 (▲), and 0.4 mM (□). (B)
Dependence of the initial rate on oxygen concentration for the M62A enzyme at choline concentrations of
1.0 (●), 0.2 (□), 0.1 (▲), and 0.02 mM (■). (C) Lineweaver−Burk plot of e/v0 as a function of the inverse of
choline concentration for the F357A enzyme at oxygen concentrations of 0.82 (●), 0.66 (▲), 0.50 (■), and
0.28 mM (○).

4.4.3 Molecular Dynamics
A CAVER analysis of the crystal structure of choline oxidase (PDB entry 4MJW)
highlighted two tunnels, A and B, leading to the isoalloxazine ring, with the side chain of F357
shaping the intersection between these two tunnels (Figure 12). Tunnel A coincides with the
previously proposed pathway taken by choline to access the active site, delimited by the side
chains of the hydrophobic cluster of M62, L65, V355, F357, and M359.86 The structural and
dynamic properties of tunnel A have been described in the previous study by Xin et al.86 The
narrow tunnel B, gated by F357 and E312, possibly represents a tunnel for the access of oxygen
to the active site.
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Figure 12. Transport pathways in the active site of choline oxidase
Transport pathways in the active site of choline oxidase (PDB entry 4MJW). Tunnels A and B are colored
orange and gray, respectively. Glycine betaine is shown as blue sticks. The side chains of M62, F357,
E312, and V464 are shown as green sticks. FAD is shown as yellow sticks.

To consider the importance of the dimer interface in helping to regulate the access of the
substrate to the active site, molecular dynamics simulations were performed on the dimeric form
of choline oxidase (PDB entry 4MJW). The goal was to accurately and efficiently study the
dynamics of the residues in the hydrophobic cluster and a newly proposed gating mechanism,
involving F357 and E312, presumed to control an entry site of oxygen into the active site. Figure
13 displays the probability distributions of the side chain torsional angles for M62, L65, V355,
F357, and M359, belonging to the hydrophobic cluster of the dimeric form of substrate-free
choline oxidase (PDB entry 4MJW). Depicted are the χ torsion angle distributions for wild-type
choline oxidase (red), the F357A variant (blue), and the M62A variant (green). The sampled
conformations for the χ torsion angles for the hydrophobic cluster residues in the M62A enzyme
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variant strongly resemble those sampled by the residues in wild-type choline oxidase (Figure
13). In Figure 13C, the sampled conformations for the χ torsion angles of V355 in the M62A
enzyme variant deviate from those sampled by the wild-type enzyme. Molecular dynamics
simulations of wild-type choline oxidase revealed that the side chains of M62 and V355 interact
through van der Waals forces. Thus, when M62 is mutated to alanine in the M62A enzyme
variant, this interaction is disrupted and the rotameric states sampled for V355 deviate more so
from those of the wild type, as depicted in Figure 13C. Overall, Figure 13 suggests that the
mutation of M62 to alanine does not significantly affect the gating mechanism of the
hydrophobic cluster proposed for choline access and glycine betaine release (tunnel A in Figure
12).
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Figure 13. Probability distributions of the side chain torsional angles for M62, L65,
V355, F357, and M359 belonging to the hydrophobic cluster of choline oxidase
Probability distributions of the side chain torsional angles for M62, L65, V355, F357, and M359 belonging
to the hydrophobic cluster of the dimeric form of substrate-free choline oxidase (PDB entry 4MJW).

47
Depicted are the χ torsion angles in the three simulations performed on wild-type choline oxidase, the
F357A, variant and the M62A variant. The simulation performed on wild-type choline oxidase is displayed
as a red line, that on the F357A variant as a blue line, and that on the M62A variant as a green line. Each
panel shows the angles for a specific residue of the hydrophobic cluster in all three simulations.

On the other hand, the distributions of the χ torsion angles sampled for the hydrophobic
cluster residues in the F357A enzyme variant deviate significantly from those sampled by the
wild-type enzyme, consistent with the side chain of F357 playing an important role in the gating
mechanism.

Figure 14. Newly proposed gating mechanism of choline oxidase presumed to control
access of oxygen to the active site
Newly proposed gating mechanism of the dimeric form of choline oxidase, involving F357 and E312,
presumed to control a site of entry of oxygen into the active site. Panels A and B show the open and closed
states, respectively. The proposed tunnel calculated by CAVER 3.0 is colored red (VDW). Choline oxidase
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is represented as a transparent pink cartoon; the hydrophobic cluster residues are colored green (VDW),
and the F357/E312 gating mechanism is colored yellow (Surf).

Figure 14 illustrates the proposed tunnel for oxygen access, controlled by the side chains
of residues F357 and E312. CAVER computed the radius of the bottleneck in tunnel B to be 1.2
Å with a tunnel length of 40.2 Å. Figure 15 illustrates the rapid dynamic motions or distance
between F357 and E312 over a 110 ns trajectory, which was conducted to investigate the
opening and closing dynamic properties of the newly proposed gating mechanism of the dimeric
form of choline oxidase. Figure 15 indicates the presence of two states, an open state and a
closed state. As can be seen, the distance between the two residues fluctuates between 3 and 9 Å.
This shows that the gate controlled by F357 and E312 does open and close dynamically. The
distribution of the shorter distances is meant to convey the presence of the closed gate, while the
distribution of the larger distances is meant to convey the presence of an opened gate. The
movements of the phenyl ring belonging to F357 determine open (Figure 14) and closed (Figure
14) states of the narrow hydrophobic tunnel gated by F357 and E312.
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Figure 15. Dynamics of residues presumed to control the access of oxygen to the choline
oxidase active site
Distance (panel A) and probability distribution (panel B) taken over time between the epsilon carbon of F357
and the delta carbon of E312, which are involved in the newly proposed gating mechanism of the dimeric
form of choline oxidase presumed to control an entry site of oxygen into the active site.

4.5

Discussion
The side chains of M62 and F357 are located at the entrance of the active site of choline

oxidase, where they are part of a hydrophobic cluster that controls the access of choline to the
active site of the enzyme.86 Recently, the crystal structure of choline oxidase in complex with the
product of choline oxidation, glycine betaine, highlighted the importance of the dimer interface
for the gating mechanism represented by the hydrophobic cluster, including M62 and F357.87An
independent study of choline oxidase using solvent viscosity effects demonstrated a catalytically
relevant isomerization of the reduced enzyme prior to reaction with oxygen during enzymatic
turnover with choline.75 In this study molecular dynamics, and steady-state kinetics have been
used to show that in choline oxidase the side chain of F357 acts as a gate for the access of
oxygen to the reduced flavin during turnover of the enzyme with choline. Gates in enzymes are
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usually defined as dynamic structural elements, such as individual residues, loops, or domains
that can reversibly switch between an open and closed state.96 These dynamic elements play
important roles in enzyme catalysis, among which are acting as molecular filters for substrate
specificity, exclusion of water molecules, and synchronization of chemical reactions.96 In the
case of the reaction of reduced flavoenzymes with oxygen, there is general consensus in the field
that structural elements in flavoenzymes participate to funnel the diffusion of this gas efficiently
to a specific site near the C4a atom of the isoalloxazine ring of the cofactor and to synchronize
and control the reaction of oxygen with the reduced flavin.69-70
The side chain of F357 controls access of oxygen to the reduced flavin of choline oxidase
through its open and closed conformations. Evidence to support this conclusion comes from the
comparison of the solvent viscosity effects on the kcat/Kox value determined with the
M62A/F357A and F357A variant enzymes and the wild-type choline oxidase. A recent study
showed that the normalized kcat/Kox value for wild-type choline oxidase decreases with an
inverse hyperbolic pattern in solvent with increasing glycerol, indicative of a relatively slow
isomerization of the reduced enzyme in the oxidative half-reaction.75 While such a mechanistic
behavior is preserved upon replacement of M62 with alanine, as shown in Figure 10, the
normalized kcat/Kox values were not affected by an increasing glycerol concentration in the
steady-state reaction mixtures with the F357A and M62A/F357A variant enzymes. These data
demonstrate that F357 is intimately associated with the isomerization seen in the oxidative halfreaction of choline oxidase, whereas M62 is not. Previous studies of flavoprotein oxidases have
identified residues at the bottleneck of transport pathways for oxygen based on structural data
and detected an increase in the Michaelis constant Kox in the variant enzymes.83-85 The study on
choline oxidase presented here further characterizes the role of a residue at the bottleneck of a
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proposed transport pathway for oxygen (F357) by using solvent viscosity studies to monitor the
isomerization of the reduced choline oxidase during the reaction with oxygen.
In silico and computational analyses of choline oxidase provide further insights at the
atomistic level into the gating mechanism for the access of oxygen to the flavin in the active site
of the enzyme. The side chain of F357 sits at the intersection of two tunnels, A and B, that
connect the enzyme surface to the flavin, as suggested by a CAVER analysis of the crystal
structure of the choline oxidase dimer in complex with glycine betaine. Tunnel A corresponds to
the proposed path for the access of choline to the active site that is delimited by the side chains
of the hydrophobic cluster composed of M62, L65, V355, F357, and M359, which was identified
in a CAVER analysis of the crystal structure of a monomer of choline oxidase in complex with
DMSO.86 Tunnel B, which is identified in this study for the first time and being narrower than
tunnel A is too small to allow access of choline to the active site, may represent the path for the
access of oxygen to the flavin in choline oxidase (Figure 12). Molecular dynamics simulations
offer support for this proposal, as the sampled conformations of the angles for residue side chains
of the hydrophobic cluster in the F357A variant enzyme deviate significantly from those sampled
in both the wild-type enzyme and the inconsequential M62A variant enzyme (Figure 13). In
wild-type choline oxidase, the side chain of F357 moved between two states that appear to
regulate the size of the bottleneck of tunnel B defined by F357 and E312 to the active site of the
enzyme in the molecular dynamics simulations. It is possible that the movement of the side chain
of F357 plays a role in directing the diffusion of oxygen to the C4a atom of the isoalloxazine to
allow flavin oxidation, as suggested by the 5-fold decrease in the kcat/Kox value of the F357A and
M62A/F357A variant enzymes that lack the phenyl group of F357, as compared to the wild-type
enzyme and the inconsequential M62A variant enzyme. Alternatively, the decrease in the kcat/Kox
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value of the enzymes in which F357 is replaced with alanine may originate from an increased
volume available to oxygen at the reaction site due to the lack of the phenyl group and
consequently a less efficient localization of oxygen near the C4a atom of the cofactor.
In summary, the contribution of the side chains of M62 and F357 in the isomerization of
reduced choline oxidase was investigated with single and double variants of the enzyme in which
the residues were replaced with alanine. The results of these studies demonstrate that the side
chain of F357 directly controls the access of oxygen to the active site of choline oxidase. In
contrast, the side chain of M62 is not involved in gating the access of oxygen to the enzymebound reduced flavin, and its replacement with alanine results in minimal changes in the kinetic
parameters of choline oxidase as compared to those of the wild-type form. This study represents
the first instance in which mutagenesis, solvent viscosity effects, steady-state kinetics, and
molecular dynamics were used to investigate the role of a specific residue in gating the access of
oxygen to the reaction site of a reduced flavoprotein oxidase during turnover.
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5

ENHANCED MOLECULAR DYNAMICS SAMPLING OF DRUG TARGET
CONFORMATIONS

5.1

Abstract
Computational docking and virtual screening are two main important methods employed

in structure-based drug design. Unlike the traditional approach that allows docking of a flexible
ligand against a handful of receptor structures, receptor flexibility has now been appreciated and
increasingly incorporated in computer-aided docking. Using a diverse set of receptor
conformations increases the chances of finding potential drugs and inhibitors. Molecular
dynamics (MD) is greatly useful to generate various receptor conformations. However, the
diversity of the structures of the receptor, which is usually much larger than the ligand, depends
on the sampling efficiency of MD. Enhanced sampling methods based on accelerated molecular
dynamics (aMD) can alleviate the sampling limitation of conventional MD and aid in
representation of the phase space to a much greater extent. RaMD-db, a variant of aMD that
applies boost potential to the rotatable dihedrals and non-bonded diffusive degrees of freedom
has been proven to reproduce the equilibrium properties more accurately and efficiently than
aMD. Here, we discuss recent advances in the aMD methodology and review the applicability of
RaMD-db as an enhanced sampling method. RaMD-db is shown to be able to generate a broad
distribution of structures of a drug target, Cyclophilin A. These structures that have never been
observed previously in very long conventional MD can be further used for structure-based
computer-aided drug discovery, and docking, and thus, in the identification and design of
potential novel inhibitors.
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5.2

Introduction
Traditionally, in structure-based drug design the time consuming chemical synthesis of

potential drug candidates is followed by in vitro drug screening in which candidates are ranked
according to their binding affinity to the drug receptor. Complementary to this approach,
computational docking and virtual screening methods are now widely used for rapid
identification of novel drug candidates.10, 97-98 In commonly used docking programs the ligands
are docked onto the receptor and the different ligand-receptor orientations are ranked according
to a scoring function that essentially assigns binding energies to the static complexes.97, 99-101
While such programs are rapid and facile to use, they are not always sufficiently accurate, as
they do not take into consideration the flexibility of the receptor and the effects of ligand binding
on receptor and solvent configurations. Most often, only the ligand is allowed to move freely.
However, recently, limited backbone and side chain dynamics of the receptor’s binding site has
been allowed, resulting in improved drug prediction.102-103
The appreciation of the fact that biomolecules are not static and are inherently flexible
has led to the development of ensemble docking methods that employ molecular dynamics to
generate an ensemble of conformations of the receptor.104-105 Docking the ligands to receptor
conformational ensemble results in a probability distribution of binding energies for each ligand
and better choice of drug candidates or potential inhibitors. Such approaches have been shown to
perform better than those that use a single or a handful of X-ray structures of a receptor.106
Standard molecular dynamics (MD) have sampling limitation and can fail to generate the
relevant and exhaustive conformational ensemble necessary for identifying the correct
compounds. Moreover, there could be a shift in the conformational ensemble (i.e.,
conformational selection) or new conformations could be induced (i.e., induced fit) upon ligand
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binding107 and such conformations may be never observed in MD simulations of the free
receptor. These induced conformations may drastically affect the binding affinities. Therefore, it
is necessary to obtain information on conformational ensemble of the receptor in a ligand-bound
state for improved drug identification and designing.108 This point has been exemplified in one of
our previous studies that show that an enzyme’s active site conformations vary as the bound
substrate changes configuration during catalytic turnover.109 Moreover, small nonpeptidomimetic inhibitors selectively bind those enzyme conformations that tightly bind the
transition state or one of the ground-state configurations of the substrate. These results suggested
that a relatively small subset of enzyme conformations that favorably binds the transition state
could be more relevant in optimizing and designing enzyme inhibitors.109
Enhanced sampling methods have been of great use in exploring the relevant regions of
the hyperdimensional conformational landscape.110 Because the energy landscape of
biomolecules is complex, comprising of many states and substates separated by barriers of
different heights, it is possible that the system may remain trapped in a particular well for a long
time or is never able to cross the barrier to reach the other state in a standard MD. The
ruggedness of the landscape due to noncovalent bond breaking and formation within the
biomolecule and between the biomolecule and the surrounding water further impedes the
exploration of the phase space.111 This may result in the lack of sufficient number of transitions
between the various states and failure to achieve Boltzmann distribution. Therefore, methods
have been developed that speed up sampling by either modification of the potential energy
surface112-117 or simulating identical molecular systems at different temperatures (i.e.,
temperature replica exchange) which is followed by intermittent swapping the conformations
sampled at varied temperatures according to Metropolis criterion.118-120 In the latter case, while
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canonical distribution is obtained at each simulated temperature, a lot of computational effort is
spent in simulating at unwanted temperatures. Under the former case which includes methods
such as umbrella sampling,112 conformational flooding,115 hyperdynamics,116 and
metadynamics,117 the potential energy surface is modified by adding a bias potential to the
Hamiltonian. In some of these methods, the phase space is restricted, i.e. prior to starting the
simulation knowledge about the reaction coordinate of the system is required. Such a
requirement is usually not straightforward to obtain for biomolecules and may be detrimental if
one desires to explore the phase space in an unconstrained manner (e.g., to obtain unexplored
conformations in case of drug binding).
5.3

Accelerated Molecular Dynamics and its Improved Variants
In this regard, accelerated molecular dynamics13 which is based on the hyperdynamics

scheme is a favorable method as it does not require restricting the phase space, i.e. sampling is
not accelerated on a single or collective predecided variable but rather in all dimensions by
adding a bias potential to the total potential energy of the system. The bias potential raises the
potential energy wells such that the effective barriers between the wells are reduced, facilitating
crossing the barriers at increased speed. The added potential does not modify the underlying
topology of the potential landscape, thus avoiding discontinuity in the modified potential that
leads to sudden increases in forces and instability in the simulation. Moreover, unlike
hyperdynamics, accelerated molecular dynamics does not involve computationally expensive
step of identifying the transition state at each time step. As compared to standard molecular
dynamics, there is a negligible computational cost of calculating the bias potential involved in
accelerated molecular dynamics. These reasons have allowed the application of accelerated
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molecular dynamics to sampling larger biomolecules. The bias potential, which has the form,
∆𝑉 (𝑟) =

(l Z 9(*))M

, is added to the original potential under these conditions:

m ` lZ9(*)

𝑉 (𝑟) + ∆𝑉 (𝑟),
𝑉 ∗ (𝑟 ) = o
𝑉 (𝑟 ),

𝑉 (𝑟 ) < 𝐸
.
𝑉 (𝑟 ) ≥ 𝐸

E is a predefined threshold boost energy, which is used as a reference to decide when the boost
should be applied to V(r). The simulation is carried out on the modified potential, V*(r), when
the potential energy V(r) is below the boost energy, E, and on the unmodified potential, V(r),
when the potential energy V(r) is above E. The potential energy, V(r), is obtained from the
summation of a subset or all of the force field terms, for example, only the total dihedral
potential. a is a preset parameter that along with E determines the level of acceleration. The
amount of acceleration applied can be explicitly varied, allowing sampling a system at different
timescales because at higher acceleration the slower modes are typically accelerated and one can
observe several long timescale events. As a tends to zero, the ruggedness of the energy landscape
is decreased and the extent of acceleration is enhanced. The modified potential tends to approach
the original potential at very large values of a. The effects of the bias can be removed after the
simulation in a straightforward manner by exponential reweighting of each configuration,
recovering the canonical ensemble. Accelerated molecular dynamics (aMD) has been applied to
investigate native-state dynamics and rare events in relatively large and complex
biomolecules.121-127 Because aMD is the only enhanced sampling method that has the provision
of tuning the level of acceleration, it has been subjected to successful experimental validation,
i.e. it could sample conformational ensemble that reproduced experimental NMR observables.121,
128
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Often, the exponential reweighting procedure results in large statistical errors when aMD
simulations are carried out for longer timescales or larger systems. A greater statistical error is
associated with reweighting if the system is subjected to a very high level of acceleration.129
Also, it has been pointed out earlier that rather than the magnitude of the bias it is important to
examine the distribution of statistical factors, i.e. bDV(r), with respect to the highest value of the
bias.129-130 If the distribution is dominated by a few data points with high statistical weights such
that there is a larger deviation between majority of the statistical weights and the highest bias,
the effective sampling size is reduced. The reduction in the sampling size will be relatively less
if the majority of the weights are closer to the highest weight. Figure 16 illustrates the relation
between statistical error and the reduction in the effective number of sampled points. In case of
NMD, the effective sample size equals the actual number of points sampled as each data point
has a weight of unity. However, Ne is less than Nx in aMD because each data point has a weight,
w = exp[bDV(r)] and the fractional loss in the effective sample size depends on the distribution
s

5

of statistical factors ( s = bDV(r)) and, i.e. 't = ∫5 w 𝑒 5Z5w 𝑝(𝑠) 𝑑𝑠. More details about this
u

x

expression can be found elsewhere.130 Based on a statistical theory,129 one can also estimate how
long one should run a simulation at a desired level of accuracy and to ensure that all the regions
below a particular threshold free energy level are sampled. Reduction in the actual number of
sampled points introduces statistical errors and thus requires running for longer times to obtain
sufficient statistics and retrieve accurate ensemble properties. Free energy profiles of Alanine
dipeptide projected along the f and y dihedrals from NMD are compared to those obtained from
aMD (Figure 16). While aMD increases the extent of sampling, the smoothness of the free
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energy contour lines is reduced, suggesting the presence of statistical error due to loss in the
sampling size, as caused by reweighting.
To address this problem of reweighting errors, aMD has been implemented by selectively
boosting only certain degrees of choice.131 Applying acceleration to a smaller number of and also
more relevant degrees of freedom leads to lowering the magnitude of the statistical weights and
thus decrease in exponential reweighting-related statistical inaccuracies, for example, applying
boost to only backbone dihedrals or just the substrate in an enzyme-substrate complex.125, 132 In a
recent variant of aMD, namely RaMD, only the rotatable dihedral angles are subjected to
acceleration.130 The degrees of freedom that mostly undergo significant variations when a
biomolecule changes conformations are the rotatable dihedral angles. The improper dihedral
angles that mainly preserve planarity and dihedral angles of the ring systems that are not
rotatable do not alter by a noticeably large extent. Therefore, in RaMD, the potential energy of
the non-rotatable and improper dihedral angles is not modified by addition of any bias. The main
advantage of RaMD is that it allows for simulating a biomolecular system in its entirety while
reducing reweighting errors. Tryptophan dipeptide that has an indole ring is an ideal model
system to assess the performance of aMD and RaMD. In a previous study, we simulated
tryptophan dipeptide with aMD and RaMD for the same length using the same level of
acceleration. Out of the total 119 dihedral angles which were all accelerated in aMD, 51 torsions
are non-rotatable and improper and thus were ignored in the RaMD treatment. Despite the fact
that only 57% of the torsions were subjected to acceleration in RaMD, the distribution of
statistical factors was shifted toward the largest weight, resulting in less loss in the sampling size
and thus statistical inaccuracy. Reweighted free energy profile from RaMD exhibited remarkably
less error that was evident from the smoother contour lines, as compared to the reweighted free
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energy plot calculated from aMD simulations (Figure 17). Moreover, RaMD was observed to
have increased sampling efficiency than aMD. To increase the applicability of RaMD to simulate
biological processes involving large length-scale and motions it was combined with the dual
boost approach that has been previously implemented with aMD.130
Essentially, in the dual boost method proposed by us, two different boosts are applied,
one to the total rotatable torsional potential and the other to the non-bonded energy terms. The
second boost speeds up the intramolecular and solvent diffusive degrees of freedom that usually
impede the rate of sampling. This method, RaMD-db,133 was tested for protein folding that
presents a very challenging sampling problem. Starting from a fully extended polypeptide chain
we could observe several folding and unfolding transitions in small fast-folding proteins and
peptides having alpha-helices as well as beta-sheets. It was remarkable that RaMD-db
implemented on general purpose hardware could capture the essential features of the folding
landscape in atomistic details and fully solvated proteins. Such folding studies have been
possible only on limitedly accessible computational resources that are specially designed and
optimized for molecular dynamics of biomolecules.134 RaMD-db, with its capability to sample
solvated systems in an efficient and accurate manner can serve as a valuable tool in conjunction
with free energy calculations in structure-based drug design.
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Figure 16. Relation between statistical error and the reduction in the effective sample
size for NMD and aMD
Loss in the effective sample size in accelerated molecular dynamics and the associated statistical error.
Shown are representative potential energy profiles in an unbiased normal molecular dynamics (NMD),
(blue), and biased simulation (aMD), (red), with respective distributions of sampled points. The diameter of
each data point is proportional to the magnitude of its statistical weight. If Nx is the number of sampled
points in window x (yellow box) with each data point associated with statistical weight, wi, and the highest
statistical weight, wh, the effective sample size, Ne, in the unbiased NMD and aMD simulations is given
}

}
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'u
'u
I
I
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Ramachandran f-y plots of Alanine dipeptide obtained from NMD (upper panel) and aMD (lower panel).
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Figure 17. Comparison of sampling and statistical errors in reweighted free energy
profiles from aMD and RaMD
Free energy profiles of tryptophan dipeptide projected on to the backbone dihedral angles calculated from
(A) aMD and (B) RaMD using the same level of acceleration. Contour lines are drawn every 1.2 kcal mol-1.

5.4

Enhanced Sampling of Potential Drug Targets with Accelerated Molecular Dynamics
Cyclophilin A (CypA) belongs to the ubiquitous family of peptidyl prolyl cis-trans

isomerases (PPIases) that is known to be involved in a host of biochemical processes such as
protein folding,135 regulation of apoptosis,34 molecular chaperone activity,136 protection of
mitochondria,137 and eliciting the immune response by binding to the transmembrane protein
CD147.138 Cis-trans isomerization is slow and is catalyzed by PPIases through stabilization of
the transition state without the formation or the breakage of any covalent bond.139 Interaction of
CypA with Cyclosporine A, an immunosuppressive and anti-rejection drug that is often given to
patients after organ transplants,140 lowers the T-cell activation and thus the immune response.
There is an increasing number of reports that specifically link CypA to various types of cancers38
mainly due to their over-expression, suggesting a potential prognostic role for CypA.141
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Moreover CypA is proposed to be a potential cancer therapeutic, as in response to
treatment with anticancer drugs, the expression levels of CypA is significantly reduced. The
other most critical role of CypA in humans is the regulation of infection by various viruses
including human immunodeficiency virus-1,39 hepatitis C virus,142 vesicular stomatitis virus,143
and severe acute respiratory syndrome virus.144 There have been ongoing efforts to discover
potent inhibitors of CypA145 and its isoforms146 that have lesser side effects and more water
solubility than the known inhibitors. Usually, inhibitors are designed from chemical compounds
that mimic the CypA substrate in the transition state configuration, without considering any
conformational changes of the enzyme when the substrate binds. Using RaMD-db, we simulated
the solvated system of CypA in the free form for 1.2 µs. CypA bound to its cognate substrat, Ser-Phe-Gly-Pro-Ala-Leu-, and a potential inhibitor ligand147 (PDB ID 3RDD) were simulated
each for 1.2-µs long using NMD, to characterize the respective conformational ensembles.
RaMD-db implemented in-house in the AMBER 14 program148 was used along with the
modified version49 of the parm99149 force field and the re-optimized parameters for the w
torsional angle50 was used. CypA was solvated in a periodic octahedral box containing TIP3P150
water molecules following which the solvated system was neutralized with chloride ions. We
used pdb structures 3RDD and 1M9F to generate the initial structures of ligand-bound CypA and
free CypA; and substrate-bound CypA, respectively (Figure 18). Minimization and equilibration
were carried out as mentioned in previous studies.132 Normal MD and RaMD-db were performed
at 300 K using the SHAKE53 algorithm to constrain all bonds involving hydrogen atoms. The
long range electrostatic interactions were evaluated via the particle mesh Ewald94 method and a
cutoff of 9.0 Å was used for the nonbonded interactions. A time step of 2 fs was used for all MD
simulations to integrate Newton’s equation of motion. For each system, the simulations were
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performed for 1.2 µs under the NVT conditions after equilibrating using NTP at a constant
pressure of 1 bar. For the RaMD-db production simulation, the boost, E, for the dihedral energy
was set at 1968 kcal mol-1, while a was set at 33 kcal mol-1. The boost for the nonbonded
interactions was set at -59175.9 kcal mol-1, while a was set at 1664.1 kcal mol-1. Details on the
choice of these parameters are included in the supporting text of a previous study.133

Figure 18. Structure of CypA with its binding site
Three-dimensional structure of CypA (gray) is shown with its active site in the VDW surface
representation. CypA conformations are depicted in the absence of a ligand (A), and when its substrate (B)
or an inhibitor (C) is present in the active site.

Examination of the conformational ensemble of CypA sampled by RaMD-db in the
absence and presence of a substrate or a ligand in its active site will reveal whether the substrate
or the ligand induces certain conformations that are hardly sampled in the free unbound form.
More CypA structures will become available for docking potential drug and inhibitor candidates
than those provided by X-ray and NMR structure determination methods. Moreover, it will
uncover any differences or similarities in the CypA conformations when the substrate is bound in
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different ground states, i.e. trans or cis, or transition state configurations. Furthermore, the
ligand-bound CypA conformations will provide useful insights in designing novel inhibitor
compounds of CypA. As a reference, we also performed standard unbiased molecular dynamics
on CypA. We analyzed the trajectories using principal component analysis (PCA) that essentially
reduces the dimensionality of the molecular dynamics data set that consists of time dependent
information on atomic coordinates. After superposition of the CypA structures from snapshots of
free and bound CypA trajectories, the covariance matrix of the Cartesian coordinates is
diagonalized to yield eigenvectors. These eigenvectors represent a new basis set generated from
linear combination of the original complex data and are ranked according to their corresponding
eigenvalues that provide the variance along the eigenvectors. Projection of the snapshots
combined from all the simulations onto the first couple of eigenvectors exhibits the predominant
atomic fluctuations and ignores the other less important modes that usually cloud the essential
features of the conformational ensemble. We performed PCA on the heavy atoms of the active
site residues: Arg55, Phe60, Met61, Gln63, Gly74, Gly75, Glu81, Lys82, Ala101, Asn102, Ala103, Thr107,
Gly109, Ser100, Gln111, Phe113, Leu122, and His126 (Figure 18A). CypA catalyzes the cis–trans
isomerization of the w bond in the Xaa-Pro motif of the substrate. These residues that recognize
the central Xaa-Pro motif and the flanking residues of the substrate define the active site and a
cavity potentially important for binding ligands. In an independent PCA analysis we selected all
the backbone C, Ca, N atoms of CypA. Projection of the trajectories on the first two PCA modes
(Figure 19) shows the two-dimensional representation of the hyper-dimensional conformational
phase space where each data point represents a CypA conformation. Remarkably, sampling of
the free CypA (Cfree) with RaMD-db was much more extensive than the conformational space
sampled by conventional MD. As expected, the conformational space of the bound CypA was
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limited and smaller than that sampled by Cfree. There was significant overlap between the
conformational ensembles of the ligand bound (Clig) and the transition-state bound (Cts) CypA. A
majority of the conformations of bound CypA were found to represent a subset of the Cfree
ensemble, suggesting that predominantly conformational selection is at play upon
ligand/substrate binding. The CypA conformations sampled by RaMD-db, which were not
observed in NMD, are interesting candidates for docking studies and open the possibility of
designing many new chemical compounds that may act as CypA inhibitors. Choice of a larger
number of CypA structures for docking potential ligands will increase the probability of finding
near-perfect fit and thus aid in speedy drug discovery. It is also possible that these CypA
conformations may bind potential ligands at sites distant from the active site and allosterically
control the binding at the active site and/or block enzyme catalysis.

Figure 19. Projection of CypA structures onto the first two principal modes
PCA was performed on heavy atoms of the active site of CypA (A) as well as on all the backbone atoms of
CypA (B). Shown are conformational ensembles of Cfree sampled by RaMD-db(blue), NMD (black), and
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CypA in complex with the substrate in the transition state (red), cis configuration (green) and the ligand
(yellow) by RaMD-db.

5.5

Conclusion
RaMD-db is an improved accelerated molecular dynamics method that allows fast,

efficient, and rigorous sampling of solvated biomolecules. Compared to aMD, the reweighting
related statistical errors to reproduce the equilibrium properties are significantly reduced when
RaMD-db is used. This enhanced sampling method can be greatly useful in generating an
exhaustive conformational ensemble of biomolecules in unliganded and ligand-bound forms.
Using representative structures from such conformational ensemble in docking studies will
increase the possibility of identifying more number of compounds that either directly bind the
active site or allosteric site distinct from the active site and thus result in the inhibition or
activation of function. In our exemplary study, we show that RaMD-db was able to sample
conformations of Cyclophilin A that were never observed in conventional MD, which can then
be targeted for novel drug discovery. Recently, Kappel et al.151 were able to show that dual-boost
aMD could significantly enhance binding of an agonist, a partial agonist, and an antagonist to the
orthosteric site of the M3 muscarinic receptor, a G-protein-coupled receptor, when compared to
conventional MD. These results suggest the usefulness of aMD in structure-based computeraided drug discovery, and docking, and thus, in the identification and design of potential novel
inhibitors.
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6
6.1

CONCLUSION

Concluding Remarks
Proteins are essential for living organisms to function.1-2 Over the years, we have tried to

uncover the many ways in which these complex biomolecules carry out their many activities.4 As
previously described, although static structures are detailed enough to provide us with
information regarding function, proteins are not static. Proteins are dynamic entities where
biological function is rooted in the internal motions and fluctuations experienced. In this work,
several case studies were performed on CypA and choline oxidase and the results emphasize the
importance of considering protein dynamics in understanding the overall function of a protein.
Overall, standard and accelerated MD methods proved to be powerful techniques capable of
acquiring a more accurate representation of the dynamic nature of the enzymes, in comparison to
the handful of snapshots provided by X-ray crystallography. On a positive note, RaMD-db, a
derivative of aMD, was able to sample protein conformations that were never observed in
standard MD. The diverse ensembles generated by MD simulations not only help characterize
the dynamic properties of proteins but also provide insight into how dynamic behavior couples
enzymatic function. For example, in one of the case studies described, particularly CypA’s,
molecular dynamics studies disclosed that the experimentally observed changes in catalytic
activity upon single-site multiple mutation of a distal region ~15 Å from the active site, were due
to a shift in the conformational/rotameric populations sampled by the active site residues. In
particular, the side chain motion of Arg55, a residue found to be important for catalysis. For
choline oxidase, studies revealed that the dynamic nature of the gate formed by F357 and E312
was necessary for catalytic turnover; it is presumed to regulate the diffusion of oxygen to the
active site which is a necessary step in the enzymatic reaction. In conclusion, atomistic level
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characterizations of protein motion or dynamics, provided by MD generated ensembles, can help
decipher the dynamics-function relationship in proteins which can lead to and facilitate novel
drug discovery, protein design, and a better understanding of a proteins participation in disease.
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